Tricida, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gerrit Klaerner
- Full Time Employees
- 57
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7000 Shoreline Court South San Francisco CA United States of America 94080
- IPO Date
- Jun 28, 2018
- CIK
- 0001595585
- Website
- tricida.com
- Similar Companies
- Business
- Tricida, Inc. was a biopharmaceutical firm dedicated to the advancement and potential commercialization of veverimer (TRC101). This investigative medicine was an orally administered, non-absorbed polymer designed to address metabolic acidosis in individuals suffering from chronic kidney disease by removing acid through the gastrointestinal tract. The company commenced operations in 2013, establishing its base in South San Francisco, California. Veverimer successfully completed Phase III clinical trials. However, in October 2022, the VALOR-CKD renal outcomes trial, which aimed to assess veverimer's effectiveness in slowing chronic kidney disease progression, did not achieve its primary endpoint. Following these developments, Tricida, Inc. filed for Chapter 11 bankruptcy liquidation in June 2023, subsequently going out of business.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tricida, Inc.
Tricida files for Chapter 11 bankruptcy protection as it searches for a buyer
Top 10 most-shorted stocks as of November 2022
What Penny Stocks Industries Are Popular Right Now?
Tricida Announces Third Quarter 2022 Financial Results
Tricida Announces Third Quarter 2022 Financial Results
What to Look For in Penny Stocks Under $1, 3 Tips
Buying Cheap Penny Stocks in November? 3 Tips to Use
Top Reasons You're Not Making Money With Penny Stocks
Tricida Provides Strategic Update
Tricida Provides Strategic Update
Why Is Tricida (TCDA) Stock Down 90% Today?
Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer
Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer
Tricida Announces $125 Million Debt Facility with Hercules Capital
Tricida Announces $125 Million Debt Facility with Hercules Capital
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm
Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022
Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022